CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. Conference Call and Webcast Information: Date: Wednesday, August 7, 2024 at 4:30 PM ET Participant Dial-in ...

CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. Conference Call and Webcast Information: Date: Wednesday, August 7, 2024 at 4:30 PM ET Participant Dial-in ...

CORAL GABLES, Fla., June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry.  The article is titled, "Efficacy and Safety of Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 ...

CORAL GABLES, Fla., June 10, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, will participate in a fireside chat at the 2024 Goldman Sachs Global Healthcare Conference in Miami, Florida on Wednesday, June 12, 2024, at 11:20am ET. Management will also host one-on-one investor meetings. Please find additional details about the event below. 2 ...

财务数据和关键指标变化 - 第一季度研发费用约1330万美元,较2023年同期下降约260万美元,主要是由于2023年第三季度完成长期开放标签研究310项目,以及Reliance I和III项目的完成 [21][22] - 第一季度一般及行政费用约970万美元,较2022年同期下降约260万美元,主要是由于股权激励费用的减少 [23] - 第一季度净亏损2180万美元,每股亏损0.72美元,较2023年同期的2630万美元和0.87美元有所下降 [24] - 截至2024年3月31日,公司现金、现金等价物和短期投资约8360万美元,较2023年12月31日的9630万美元有所下降,2023年第一季度经营活动使用现金1300万美元 [24] 各条业务线数据和关键指标变化 - 公司正在推进REL-1017用于治疗主要抑郁障碍的两项III期临床试验Reliance II和Relight,预计Reliance II将于今年下半年完成并获得结果 [10][12][13] - 公司已完成REL-1017的所有必要的临床前制造和I期研究,目前正专注于执行剩余的两项III期试验 [15] - 公司还在推进一种新型改良释放型的psilocybin项目,计划于今年上半年启动I期单剂量递增试验,并于2025年上半年获得II期临床试验结果 [16][18] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司坚信REL-1017是一种可获批准的药物,并对其新型psilocybin衍生物项目充满信心 [77] - 公司正在密切监控临床试验中的患者数据质量,对于出现不一致性的试验点采取关闭等措施,以提高试验成功的可能性 [28][29][38][39] - 公司所在适应症领域的竞争相对较小,但也面临一些来自其他适应症的间接竞争,如精神病和癫痫领域的一些延迟 [55][56] 管理层对经营环境和未来前景的评论 - 公司目前处于重要的发展阶段,未来12-18个月内将有多个重要里程碑,包括Reliance II试验结果和psilocybin I期试验启动 [18] - 公司目前处于良好的财务状况,现金储备可以支持到2025年 [19] 问答环节重要的提问和回答 问题1 **Basma Radwan 提问** 公司如何监控Reliance和Relight试验的盲态数据,并采取措施来降低安慰剂反应 [27] **Sergio Traversa 和 Andrew Cutler 回答** 公司会密切监控试验数据,关注患者MADRS评分的波动情况,这可能表明某些问题。公司会与试验点沟通,必要时关闭存在质量问题的试验点,以提高试验成功的可能性 [28][29][31][32][33][39] 问题2 **Andrea Tan 提问** 如果发现试验点存在问题,公司具体会采取哪些措施 [37] **Sergio Traversa 和 Andrew Cutler 回答** 公司会首先与试验点沟通,了解情况,如果问题持续存在,公司会停止该试验点的患者入组,以免影响整个试验 [38][39] 问题3 **Andrew Tsai 提问** 公司是否会进行中期分析或者由DSMB建议提前终止试验 [40] **Sergio Traversa 和 Andrew Cutler 回答** 公司不会进行正式的中期分析,但DSMB会在接近试验结束时对数据进行简单的重新评估,看是否需要扩大样本量。DSMB的主要职责是监控安全性,目前安全性和耐受性数据看起来很好 [41][42]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission File Number: 000-55347 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charte ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Conference Call March 19, 2024 4:30 PM ET Company Participants Tim McCarthy - IR, Advisors Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Basma Radwan - Leerink Partners Uy Ear - Mizuho Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Relmada Therapeutics Inc. Fourth Quarter and Full Year 2023 Results Call. At this time, all lines are in a listen-only mode. F ...

Exhibit 99.1 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results CORAL GABLES, Fla., Mar 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023. The Company will host a conference call today, Tue ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 45-5401931 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identi ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Results Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Tim McCarthy - Investor Relations, Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Cedric O'Gorman - Chief Medical Officer Conference Call Participants Basma Radwan - SVB Leerink Charles Wang - Mizuho Securities Dina Elmonshed - Jefferies Operator Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Qua ...